Latest Safety News

Radiopharm Theranostics has received a positive recommendation to escalate the dose of its 177Lu-RAD202 radiotherapeutic in a Phase 1 trial targeting HER2-positive advanced solid tumors, maintaining its timeline to complete dose escalation by year-end 2026.

Perenti Limited has secured a 12-month extension of its underground mining services contract with Regis Resources at the Duketon Operations, increasing contract value by approximately A$180 million and extending the term to at least March 2029 without additional capital requirements.

Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.

Etherstack’s Australian subsidiary Auria Wireless has landed a multi-year contract with the Department of Home Affairs, valued at around A$9 million initially and potentially rising to A$15 million with extensions.

Fiducian Group Limited has responded to a sharp share price drop by denying any undisclosed information and downplaying the impact of new APRA licence conditions on its operations.

Emyria Limited has launched a targeted recruitment campaign in New South Wales to establish its fourth state-based clinical operation, aiming to tap into Australia's largest mental health market amid rising psychological injury claims.

Beetaloo Energy has received a $15.4 million R&D tax refund, reinforcing its financial position as it advances key milestones in the Carpentaria Pilot Project towards gas production and sales in 2026.

Arovella Therapeutics has demonstrated that its novel CLDN18.2-targeting CAR incorporated into iNKT cells effectively eliminates pancreatic and gastric cancer cells in vitro, with IL-12-TM armouring enhancing potency and durability.

AdAlta’s BZDS1901 CAR-T therapy shows remarkable tumour shrinkage and complete responses in advanced mesothelioma patients, doubling expected outcomes and paving the way for higher dosing and expanded trials.

Actinogen Medical has initiated the open-label extension of its XanaMIA Alzheimer’s trial, offering all participants active Xanamem treatment for up to 25 months to gather long-term safety and efficacy data ahead of final trial results.

GoldArc Resources has secured a key tenement adjacent to its high-grade Whistler and Woodpecker South prospects in the Kookynie Goldfields, expanding its Leonora South project at a modest cost. This acquisition complements ongoing drilling programs that have already delivered impressive gold assay results.

Racura Oncology has enrolled the first patient in its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib to tackle resistance in EGFR-mutant non-small cell lung cancer. This milestone sets the stage for a multi-centre study aiming to improve treatment outcomes.